0K3.F - TFF Pharmaceuticals, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.4980
-0.0320 (-6.04%)
At close: 09:15AM CEST
Stock chart is not supported by your current browser
Previous Close0.5300
Open0.4980
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's Range0.4980 - 0.4980
52 Week Range0.4820 - 6.4000
Volume640
Avg. Volume11
Market Cap18.024M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.7700
Earnings DateAug 09, 2023 - Aug 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • GlobeNewswire

    TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

    FORT WORTH, Texas, May 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that CEO Harlan Weisman, M.D. will be presenting a corporate overview at the 2023 Jefferies Healthcare Conference being held in-person in New York, NY on June 7-9, 2023. Company management will also be participating in

  • GlobeNewswire

    TFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

    Initial Phase 2 data for TFF VORI and TFF TAC expected later this yearExpanded compassionate use program for TFF VORIEntered into CRADA with National Institute of Environmental Health Sciences Extended contract with Leidos providing additional funding for TFF’s development of next-generation countermeasuresImplemented reduced spending initiatives to extend cash runway through year-end FORT WORTH, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a

  • ACCESSWIRE

    Sidoti's Micro-Cap Virtual May Conference

    Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject to change, please visit www.sidoti.com/events for the most updated version and webinar links.

  • GlobeNewswire

    TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases

    FORT WORTH, Texas, May 04, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has entered into a Collaborative Research and Development Agreement (CRADA) with the National Institute of Environmental Health Sciences (NIEHS) to develop respirable, dry powder formulati

  • GlobeNewswire

    TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program

    FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Leidos, a leading Fortune 500 information technology, engineering and science solutions and services leader, has awarded the Company additional funding under the DARPA Personalized Protective

  • Simply Wall St.

    We're A Little Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Rate

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results

    FORT WORTH, Texas, March 07, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported fourth quarter and full year 2022 financial results. “TFF Pharmaceuticals is pursuing our new product development strategy and we are focused on advancing our two lead clinical candidates, Inhale

  • GlobeNewswire

    TFF Pharmaceuticals to Participate in the 35th Annual Roth Conference

    FORT WORTH, Texas, March 06, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that CEO Harlan Weisman, M.D. will be participating in a Fireside Chat at the 35th Annual Roth Conference being held in-person at The Ritz Carlton, Laguna Niguel in Dana Point on March 12-14, 2023. Company management

  • GlobeNewswire

    TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

    Dr. Harlan Weisman and recently appointed Chief Medical Officer Dr. Zamaneh Mikhak to Provide an Overview of the Corporate Strategy and 2023 Objectives Conference Call and Webcast Scheduled for Thursday, February 16, 2023, 4:30 p.m. ET FORT WORTH, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platfor

  • GlobeNewswire

    TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer

    FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer. Dr. Mikhak will be responsible for the clinical development of the Company’s pipeline candidates, including the Inhaled Voriconazole Powder and Inhaled

  • GlobeNewswire

    TFF Pharmaceuticals Announces Leadership Transition

    Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer FORT WORTH, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that Glenn Mattes will ste

  • GlobeNewswire

    TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering

    Underwriters Exercise Their Option in FullFORT WORTH, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced underwritten offering of 10,675,001 shares of its common stock and warrants to purchase up to 5,337,501 shares of common stock. T

  • GlobeNewswire

    TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

    FORT WORTH, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has priced a $10.675 million underwritten offering of 9,282,609 shares of its common stock and warrants to purchase up to 4,641,305 shares of common stock. The warrants are being sold at the rate of one

  • GlobeNewswire

    TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

    FORT WORTH, Texas, Nov. 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it is offering to sell shares of its common stock and warrants to purchase common stock in an underwritten public offering. All of the securities in the offering are being sold by the TFF Pharmaceuticals, I

  • GlobeNewswire

    TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

    Clinical Proof-of-Concept Demonstrated in Compassionate Use in Two Case Studies with Voriconazole Inhalation Powder (TFF VORI) Growing Body of Peer-Reviewed Scientific Literature Provides Foundations for Expanding Applications of Thin Film Freezing Feasibility Study Agreement with Aptar Pharma to Explore Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics Conference Call and Webcast Scheduled Today, Monday, November 14, 2022, at 4:30 PM ET FORT WORTH, Texas, Nov. 14, 2022 (GLO

  • GlobeNewswire

    TFF Pharmaceuticals to Hold Third Quarter 2022 Financial and Business Results Conference Call on November 14, 2022

    Company conference call and webcast at 4:30 PM ET FORT WORTH, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it will release its financial results and business update for the third quarter of 2022 on Monday, November 14, 2022, at the close of the U.S. financial markets.

  • GlobeNewswire

    TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics

    Administration of dry powders will utilize Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System The TFF dry powder vaccines maintain the antigen’s integrity, can be delivered to the targeted region of the nasal cavity, and have desirable particle size distribution, spray pattern and plume geometry A shelf-stable dry powder vaccine formulation delivered intranasally could dramatically change the existing vaccine landscape FORT WORTH, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals,

  • GlobeNewswire

    TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

    Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder (TFF VORI) Using Thin Film Freezing-Based Technology Positive Results from First Patient Treated with TFF VORI Recently Presented at the 15th Annual International Congress on Lung Transplantation FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug product

  • GlobeNewswire

    TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical Programs

    FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced program updates for Voriconazole Inhaled Powder (TFF VORI) and Tacrolimus Inhaled Powder (TFF TAC) clinical programs. We expect to deliver preliminary patient data from the Phase 2 study of TFF VORI in the first

  • Simply Wall St.

    Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

    Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of Monoclonal Antibodies and Applications of Machine Learning to Predict Aerosol Performance of Dry Powders for Inhalation Highlights the Company’s Strategic Focus of Expanding its Biologics Product Portfolio FORT WORTH, Texas, Oct. 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a

  • GlobeNewswire

    TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference

    FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the Roth Inaugural Healthcare Opportunities Conference being held in-person at The Yale Club in New York City on October 6, 2022. Company management

  • GlobeNewswire

    TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

    Two Abstracts Selected for Presentation as part of the Meeting’s Special Poster Collections Research Focuses on the Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of Monoclonal Antibodies and Applications of Machine Learning to Predict Aerosol Performance of Dry Powders for Inhalation FORT WORTH, Texas, Sept. 22, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative

  • GlobeNewswire

    TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation

    Dr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia presented results from compassionate use of treating pulmonary fungal infections in a lung transplant patient Patient previously intolerant to oral voriconazole therapy successfully treated with TFF VORI FORT WORTH, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its p

  • GlobeNewswire

    TFF Pharmaceuticals to Participate at The H.C. Wainwright 24th Annual Global Investment Conference

    FORT WORTH, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held September 12 – 14, 2022 at the Lotte New York Palace in New York City. Compan